39736-29-3

Usage

Synthesis Reference(s)

Tetrahedron Letters, 7, p. 1885, 1966 DOI: 10.1016/0005-2760(66)90119-6

InChI:InChI=1/C7H10N2O2S2/c1-3-11-6(10)4-5(8)9-7(12-2)13-4/h3,8H2,1-2H3

Upstream product

• 10191-61-4 potassium S-methyl N-cyanocarbamodithioate 
• 105-39-5 chloroacetic acid ethyl ester 
• 623-51-8 ethyl 2-sulfanylacetate 
• 10191-60-3 dimethyl N-cyanodithioiminocarbonate 
• 10191-61-4 potassium methyl cyanoiminodithiocarbonate 
• 105-36-2 ethyl bromoacetate 
• 10191-67-0 C₇H₁₀N₂O₂S₂ 
• 84911-18-2 ethyl 2-bromoacetoacetate 
• 55919-47-6 ethyl 2-bromo-3-oxo-3-phenylpropionate 
• 13145-41-0 potassium cyanocarbonimidodithioate 
• 74-88-4 methyl iodide 

Downstream Products

• 94507-74-1 4-Amino-2-methylthiothiazole-5-carboxylic Acid 
• 147235-59-4 ethyl 2-methylthio-4-[(triphenylphosphanylidene)amino]thiazole-5-carboxylate 
• 1329991-68-5 C₁₄H₁₄ClN₃O₄S₂ 
• 1329991-69-6 C₁₄H₁₆ClN₃O₂S₂ 
• 1329991-71-0 C₁₈H₁₄ClN₃OS₂ 
• 1329991-72-1 C₁₈H₁₄ClN₃O₃S₂ 
• 1329991-73-2 C₁₄H₁₄ClN₃O₆S₂ 
• 1329991-74-3 C₁₃H₁₂ClN₃O₄S 
• 119011-56-2 7-Chlor-2-(methylthio)thiazolo<4,5-d>pyrimidin 
• 1228102-97-3 N-(3-(4-methoxybenzyloxy)phenyl)-2-(methylthio)thiazolo[4,5-d]pyrimidin-7-amine 
• 152300-59-9 ethyl 4-amino-1,3-thiazole-5-carboxylate 
• 1443014-87-6 ethyl 4-bromo-2-(methylsulfanyl)-1,3-thiazole-5-carboxylate 

Relevant academic research and scientific papers

Growth Factor Receptor antagonists. Preparation method and application thereof

The invention relates to a small molecule antagonist for transforming growth factor β receptors, a method for preparing the small molecule antagonist, and application of the small molecule antagonist in preparation of drugs. The small molecule antagonist for transforming the growth factor β receptor has the application of treating and/or preventing various diseases mediated by ALK5, and has great clinical application potential.

Design, synthesis and biological evaluation of novel thiazole-based derivatives as human Pin1 inhibitors

Pin1 is a peptidyl prolyl cis-trans isomerase (PPIase) and inhibiting Pin1 is a potential way for discovering anti-tumor agents. With an aim to find potent Pin1 inhibitors with a novel scaffold, a series of thiazole derivatives with an alicyclic heterocycles on the 2-position were designed, synthesized and tested against human Pin1. Compound 9p bearing a 2-oxa-6-azaspiro [3,3] heptane moiety on the thiazole scaffold was identified as the most potent Pin1 inhibitor of this series with an IC50 value of 0.95 μM. The structure-activity relationship (SAR) and molecular modeling study indicated that introducing an alicyclic ring with an H-bond acceptor would be a viable way to improve the binding affinity.

Synthesis method of ethyl 4-amino-2-(methylthio)thiazole-5-carboxylate

The invention belongs to the technical field of pharmaceutical intermediates, and relates to a synthesis method of ethyl 4-amino-2-(methylthio)thiazole-5-carboxylate. The method includes the followingsteps that an aqueous solution of cyanamide is mixed with ethanol, carbon disulfide and a potassium hydroxide solution are added for reaction, and a precipitated solid is subjected to suction filtration and drying to obtain an intermediate A; the intermediate A is dissolved in a mixed solution of ethanol and water, an iodomethane ethanol solution is dropped for reaction, and an intermediate B isobtained through concentration and drying; the intermediate B, ethyl chloroacetate and triethylamine are subjected to a reflux reaction in ethanol, and the obtained solution is concentrated, washed and re-crystallized to obtain ethyl 4-amino-2-(methylthio)thiazole-5-carboxylate. The cost of raw materials is low, the yield of by-products is low, the product yield is high, and the method is suitablefor scale-up production.

Synthesis and Pin1 inhibitory activity of thiazole derivatives

Pin1 (Protein interacting with NIMA1) is a peptidyl prolyl cis–trans isomerase (PPIase) which specifically catalyze the conformational conversion of the amide bond of pSer/Thr-Pro motifs in its substrate proteins and is a novel promising anticancer target. A series of new thiazole derivatives were designed and synthesized, and their inhibitory activities were measured against human Pin1 using a protease-coupled enzyme assay. Of all the tested compounds, a number of thiazole derivatives bearing an oxalic acid group at 4-position were found to be potent Pin1 inhibitors with IC50values at low micromolar level. The detailed structure–activity relationships were analyzed and the binding features of compound 10b (IC505.38 μM) was predicted using CDOCKER program. The results of this research would provide informative guidance for further optimizing thiazole derivatives as potent Pin1 inhibitors.

BIARYL COMPOUNDS USEFUL FOR THE TREATMENT OF HUMAN DISEASES IN ONCOLOGY, NEUROLOGY AND IMMUNOLOGY

The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.

ANTI-INFECTIVE COMPOUNDS

The present invention relates to small molecule compounds having the general formula (I): wherein A is a moiety selected from the group consisting of formulae (A) to (K) and their use in the treatment of bacterial infections, in particular Tuberculosis.

NBS-mediated sequential one-pot synthesis of multifunctionalized thiazoles and thiophenes from 1,3-dicarbonyl compounds and mercaptonitrile salts

A NBS-mediated sequential one-pot synthesis of multifunctionalized thiazoles and thiophenes from 1,3-dicarbonyl compounds and mercaptonitrile salts has been developed under mild conditions. This transformation involves sequential bromination/SN

ANTI-INFLAMMATORY COMPOUND HAVING INHIBITORY ACTIVITY AGAINST MULTIPLE TYROSINE KINASES AND PHARMACEUTICAL COMPOSITION CONTAINING SAME

The present invention is for the anti-inflammatory compounds that have an inhibitory activity against protein tyrosine kinases and their pharmaceutical composition(s) containing the compound as the active ingredient. Since the compounds of the present invention can inhibit multiple protein kinases associated with inflammatory diseases and immune disorders, they are useful for their prevention or treatment.

4-Bromo-2-(piperidin-1-yl)thiazol-5-yl-phenyl methanone (12b) inhibits Na+/K+-ATPase and Ras oncogene activity in cancer cells

The in vitro growth inhibitory activity of 26 thiazoles (including 4-halogeno-2,5-disubtituted-1,3-thiazoles) and 5 thienothiazoles was assessed on a panel of 6 human cancer cell lines, including glioma cell lines. (4-Chloro-2-(piperidin-1-yl)thiazol-5-yl)(phenyl)methanone (12a) and (4-bromo-2-(piperidin-1-yl)thiazol-5-yl)(phenyl)methanone (12b) displayed ～10 times greater in vitro growth inhibitory activity than perillyl alcohol (POH), which therapeutically benefits glioma patients through the inhibition of both alpha-1 Na+/K+-ATPase (NAK) and Ras oncogene activity. The in vitro cytostatic activities (as revealed by quantitative videomicroscopy) displayed by 12a and 12b were independent of the intrinsic resistance to pro-apoptotic stimuli associated with cancer cells. Compounds 12a and 12b displayed relatively similar inhibitory activities on purified guinea pig brain preparations that mainly express NAK alpha-2 and alpha-3 subunits, whereas only compound 12b was efficacious against purified guinea pig kidney preparations that mainly express the NAK alpha-1 subunit, which is also expressed in gliomas, melanomas and non-small-cell lung cancers NSCLCs.

DERIVATIVES OF 1-PHENYL-1,5-DIHYDRO-BENZO[B] [1.4]DIAZEPINE-2.4-DIONE AS INHIBITORS OF HIV REPLICATION

Compounds of formula (I) wherein m, R1, R2, R3, X and Y are defined herein, are useful as inhibitors of HIV replication.